// App-Quantinova.ai

: Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

Researchers

Presenter

  • M.Lia Palomba

Principal Investigators

  • Toby A. Eyre

  • Wojciech Jurczak

  • David John Lewis

  • Thomas Gastinne

  • Shuo Ma

  • Jonathon B. Cohen

  • Krish Patel

  • Jennifer R. Brown

  • Lydia Scarfo

  • Talha Munir

  • Ewa Lech-Maranda

  • Marc Hoffmann

  • Chaitra S. Ujjani

  • Bita Fakhri

  • Michael L. Wang

  • Koji Izutsu

  • Hirokazu Nagai

  • Constantine S. Tam

  • John F. Seymour

  • Joanna M. Rhodes

  • Julie M. Vose

  • Matthew McKinney

  • James N. Gerson

  • Minal A. Barve

  • Bryone J. Kuss

  • Youngil Koh

  • Wei Gao

  • Amy S. Ruppert

  • Richard A. Walgren

  • Donald E. Tsai

  • Binoj Nair

  • Katherine Bao

  • Anthony R. Mato

  • Chan Y. Cheah

Medical Centers

  • University of Texas, MD Anderson Cancer Center, Houston, TX

  • University of Nebraska Medical Center, Omaha, NE

  • Duke Cancer Institute, Durham, NC

  • Northwell Health Cancer Institute, New Hyde Park, NY

  • Swedish Cancer Institute, Seattle, WA

  • Centre Hospitalier Universitaire de Nantes, Nantes, France

  • National Cancer Center Hospital, Tokyo, Japan

  • Plymouth Hospitals NHS Trust - Derriford Hospital, Plymouth, United Kingdom

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston

  • University of California San Francisco Medical Center, San Francisco, CA

  • National Hospital Organization Nagoya Medical Center, Nagoya, Japan

  • Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL

  • Indianapolis, IN

  • Winship Cancer Institute, Emory University, Atlanta, GA

  • Department of Haematology, St. James's University Hospital, Leeds, United Kingdom

  • Institute of Hematology and Transfusion Medicine, Warsaw, Poland

  • Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia

  • Flinders University Medical Centre, Bedford Park, Australia

  • Fred Hutchinson Cancer Center, University of Washington, Seattle, WA

  • Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

  • Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL

  • Università Vita-salute San Raffaele and IRCC Ospedale San Raffaele, Milan, Italy

  • Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia

  • Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom

  • Seoul National University Hospital, Seoul, Korea, Republic of (South)

  • Memorial Sloan Kettering Cancer Center, New York, NY

  • Mary Crowley Cancer Research Center, Dallas, TX

  • Lymphoma Program, Abramson Cancer Center, Philadelphia, PA

  • The University of Kansas Cancer Center, Kansas City, KS

Locations

  • United States

  • Australia

  • Poland

  • United Kingdom

  • Republic of South Korea

  • Japan

  • France

  • Italy

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

Biomarkers

  • Bruton tyrosine kinase

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Multicenteric

  • Dose Escalation

  • Cohort

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved